Continuous Vital Sign Monitoring During Admission for Acute Exacerbations of Chronic Obstructive Pulmonary Disease - an Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- Any serious adverse events
研究概览
简要总结
For patients admitted to the medical ward, it is often difficult to predict if their clinical condition will deteriorate, however subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to ICU admission, or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. The WARD-COPD project aims to determine the correlation between cardiopulmonary micro events and clinical adverse events during the first four days after hospital admission with acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 100 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients admitted with AECOPD
- •Recruitment and monitoring start is possible within 24 hours after admission
排除标准
- •Patient expected not to cooperate
- •Patient allergic to plaster, plastic or silicone
- •Active therapy withdrawn
- •Patients with dementia or not able to give informed consent
- •Patients with pacemaker or implantable cardioverter-defibrillator (ICD) unit
- •Expected discharge within less than 24 hours from possible inclusion
结局指标
主要结局
Any serious adverse events
时间窗: within 30 days after inclusion
E.g. cardiac arrest, ICU admission, acute myocardial infarction, stroke, sepsis, acute kidney injury or other serious adverse events (defined in Protocol Appendix A)
次要结局
- Readmission(within 6 months after inclusion)
- Mortality(within 6 months after inclusion)
研究者
Mikkel Elvekjaer
MD
University Hospital Bispebjerg and Frederiksberg
